MediPharm Names Greg Hunter Chief Executive
Hunter, who has led the company as interim CEO since January 2026, will take the permanent role effective November 4, 2026.
Updated on Nov. 4, 2026 in People
MediPharm Labs has appointed Greg Hunter as Chief Executive Officer and a member of its Board of Directors, effective November 4, 2026. Hunter served as Interim Chief Executive Officer since January 2026 and will continue as Chief Financial Officer until a successor is appointed.
Why it matters
The Board concluded that Hunter is well positioned to lead MediPharm into its next phase following a thorough evaluation process. The move gives the Toronto-based cannabis and pharmaceutical company a permanent leader after several months under an interim arrangement.
Hunter joined MediPharm as Chief Financial Officer in February 2021 and has more than 20 years of experience in healthcare, manufacturing and consumer businesses. A successor Chief Financial Officer has not yet been named, and the timing of that appointment was not disclosed.
The players
Greg Hunter
Hunter is MediPharm Labs' incoming Chief Executive Officer, bringing more than 20 years of experience across healthcare, manufacturing and consumer businesses, including earlier leadership roles at Johnson & Johnson and Baxter.
MediPharm Labs
MediPharm Labs is a Toronto-based company founded in 2015 that holds a Health Canada Pharmaceutical Drug Establishment Licence and acquired VIVO Cannabis Inc. in 2023.
Keith Strachan
Strachan is Chair of the Board of Directors of MediPharm Labs, overseeing the board that appointed Hunter as chief executive.
The details
Hunter previously held leadership roles with Johnson & Johnson and Baxter before joining MediPharm. Keith Strachan, Chair of the Board, is part of the governance structure overseeing the appointment, and the company says it expects to continue executing its plan for profitable growth, operational excellence and long-term value creation.
Timeline
2015: MediPharm Labs was founded.
February 2021: Hunter joined MediPharm as Chief Financial Officer.
January 2026: Hunter began serving as Interim Chief Executive Officer.
November 4, 2026: Hunter's appointment as Chief Executive Officer takes effect.
Market Landscape
MediPharm's leadership change follows its 2021 Health Canada Pharmaceutical Drug Establishment Licence, which positioned the company to pursue pharmaceutical rather than only cannabis-based activity. The 2023 acquisition of VIVO Cannabis Inc. further consolidated its position within Canada's regulated cannabis and pharmaceutical sector.
For investors and shareholders, the permanent CEO appointment removes uncertainty that came with an interim leadership arrangement that began in January 2026. Investor relations can be reached at 1-416-913-7425 for questions about the company's direction under its new leadership.
The takeaway
Leadership continuity matters for companies moving through regulatory milestones and acquisitions, and MediPharm's board has chosen to make its interim chief executive permanent. Readers following the company can track the coming Chief Financial Officer appointment as the next test of its leadership transition.
What happens next
A successor Chief Financial Officer is to be appointed, after which Hunter will complete an orderly transition from that role; no date for the appointment was provided.
Further reading
For more on executive moves across the sector, browse People coverage on Wisevoter.
